Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.43 |
| ▸ | CA12 | O43570 | 2/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | CA9 | Q16790 | 2/20 | 0.33 |
| ▸ | FLT3 | P36888 | 2/20 | 0.33 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.33 |
| ▸ | KIT | P10721 | 1/20 | 0.33 |
| ▸ | BCR | P11274 | 1/20 | 0.33 |
| ▸ | SMAD3 | P84022 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20084046 | 0.82 | GRIN2D (0.41) | FLT3PDGFRB | |
| SCHEMBL20084276 | 0.82 | EIF4A3 (0.41) | GPR35 | |
| SCHEMBL18332470 | 0.79 | FLT3 (0.30) | FLT3 | |
| SCHEMBL18331683 | 0.77 | NPSR1 (0.40) | GPR35MAPT | |
| SCHEMBL20084975 | 0.77 | PDE10A (0.31) | — | |
| SCHEMBL18332229 | 0.76 | POLB (0.36) | MAPT | |
| SCHEMBL18331842 | 0.76 | SRD5A1 (0.30) | — | |
| SCHEMBL20084909 | 0.76 | PYGL (0.32) | — | |
| SCHEMBL18332149 | 0.76 | GPR35 (0.44) | GPR35CA12CA1CA2CA9 | |
| SCHEMBL16015322 | 0.74 | FLT3 (0.57) | FLT3PDGFRBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3312172-B1 | AMINOPYRAZOLE DERIVATIVES USEFUL AS SRC KINASE INHIBITORS | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2020-05-06 | — | — | EP | disclosed |
| US-10479780-B2 | Aminopyrazole derivatives | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2019-11-19 | — | — | US | disclosed |
| EP-3312172-A1 | AMINOPYRAZOLE DERIVATIVES | Chugai Seiyaku Kabushiki Kaisha (JP) | 2018-04-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10479780-B2 | Aminopyrazole derivatives | SRC, GRK2, GRK3 | GPR35 399/4885CA12 4725/4885CA1 4757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.